特立帕肽
透皮
医学
口腔给药
药物输送
叙述性评论
药品
生物利用度
药理学
重症监护医学
骨质疏松症
纳米技术
内科学
材料科学
骨矿物
作者
Neeraj Mittal,Gajanand Sharma,O. P. Katare,Sanjay Kumar Bhadada
出处
期刊:Critical Reviews in Therapeutic Drug Carrier Systems
[Begell House Inc.]
日期:2023-01-01
卷期号:40 (6): 117-140
被引量:1
标识
DOI:10.1615/critrevtherdrugcarriersyst.2023045480
摘要
In the field of pharmaceutical biotechnology and formulation development, various protein and peptide-based drugs have been used for therapeutic and clinical implications. These are mainly given via parenteral routes like intravenous, subcutaneous or intramuscular delivery. Teriparatide, also known as PTH 1-34, is a U.S. Food & Drug Administartion-approved anabolic drug to treat osteoporosis is currently available in market only as subcutaneous injection. The quest for elimination of needle in case of given peptidal delivery to replace it with alternative routes like nasal, buccal, transdermal and pulmonary pathways has driven meticulous drug research. The pharmaceutical scientists are working on innovation and approaches involving new materials and methods to develop the formulations for protein and peptides by noninvasive routes. Lately, various approaches have been carried out which involve many strategies and technologies to deliver teriparatide via alternative routes. But, physicochemical instability, proteolytic degradation, low bioavailability, etc. are some obstacles to develop suitable delivery system for teriparatide. This review intends to gather the overall developments in delivery systems specific to teriparatide which meant for better convenience and avoids vulnerability of multiple subcutaneous injections. In addition, the article emphasizes on the successes to develop noninvasive technologies and devices, and new milestones for teriparatide delivery.
科研通智能强力驱动
Strongly Powered by AbleSci AI